Recent recommendations of the European Society of Pathology, the European Organization for Research and Treatment of Cancer, and the EURACAN for the diagnosis of intermediate melanocytic proliferations and melanoma variants indicate that most pathology laboratories should perform basic IHC tests, such as: HMB-45; SOX10; MITF, tyrosinase, MART-1; P16; Ki-67/MIB1; BAP1 (BRCA1-associated protein 1); β-catenin; PRAME; and at least one molecular method to detect BRAF codon 600 and NRAS mutations [42]. This evidence concerns the gene CDKN2A and melanoma.